Jul. 15 at 1:31 AM
$TLRY The Bull Case:
Massive Valuation Disconnect: The consensus Wall Street price target sits at
$11.50, representing a substantial upside from its current trading price of
$4.38.
U.S. Infrastructure Advantage: Its craft beverage business gives Tilray an active, state-compliant distribution network across the U.S. If federal legalization occurs, Tilray can pivot this infrastructure to THC-infused beverages faster than its competitors.
Short Squeeze Potential: With a high short interest of 15.40% and 5.3 days to cover, any positive surprise during the July 28 earnings report or sudden positive U.S. political news could trigger a violent upward rally as short sellers panic to buy back shares.
Global Medical Growth: Tilray is a dominant leader in Europe, particularly in Germany's rapidly expanding medical cannabis market, which protects it from being entirely dependent on U.S. regulatory timelines.
